Supplementary Table 4. Univariate Analysis to Predict Endoscopic Remission

Variable	Endoscopic non-remission (n = 29)	Endoscopic remission (n = 8)	*P*-value
Sex, No. (%)			0.068
Male	14 (48)	1 (13)	
Female	15 (52)	7 (88)	
Age (yr), mean ± SD	45.28 ± 13.25	37.13 ± 13.36	0.133
Induction medication, No. (%)[a]			0.195
Corticosteroids	20 (69)	6 (75)	
VDZ	6 (21)	1 (13)	
IFX	0	0	
JAK1 inhibitor	3 (10)	0	
Maintenance medication, No. (%)			0.316
Aminosalicates	6 (21)	3 (38)	
VDZ	14 (48)	3 (38)	
IFX	6 (21)	0	
JAK1 inhibitor	3 (10)	2 (25)	
BMI (kg/m^2), mean ± SD	21.43 ± 3.28	20.42 ± 1.84	0.476
Disease duration (yr), mean ± SD	5.79 ± 6.01	5.07 ± 6.72	0.782
Mayo endoscopic score	2.72 ± 0.45	2.88 ± 0.35	0.334
Biochemical parameters at baseline, mean ± SD			
CRP (mg/L)	37.46 ± 56.69	40.56 ± 60.61	0.893
ESR (mm/hr)	37.18 ± 29.90	38.43 ± 28.69	0.921
Hemoglobin (g/L)	110.24 ± 28.22	102.88 ± 31.64	0.528
Leukocytes (10^9/L)	7.27 ± 3.50	9.35 ± 3.76	0.152
Thrombocytes (10^9/L)	310.76 ± 117.41	404.13 ± 163.79	0.076
Albumin (g/L)	35.93 ± 6.03	33.75 ± 6.76	0.383
CRP at second IUS, mean ± SD	4.95 ± 8.59	3.56 ± 6.40	0.693
△CRP, mean ± SD	33.84 ± 58.74	42.45 ± 65.08	0.737
IUS parameters at baseline			
BWT, mm, mean ± SD	7.3 ± 1.8	7.6 ± 1.2	0.651
Limberg, No. (%)			0.721
Limberg = 0	1 (3)	0	
Limberg = 1	4 (14)	0	
Limberg = 2	9 (31)	2 (25)	
Limberg = 3	7 (24)	3 (38)	
Limberg = 4	8 (28)	3 (38)	
MUC, mean ± SD	11.9 ± 3.0	12.7 ± 1.7	0.478
Wall layer stratification, No. (%)			0.141
Loss	13 (45)	1 (13)	
Blurred	8 (28)	5 (63)	
Clear	8 (28)	2 (25)	

(Continued to the next page)

Table 4. Continued

Variable	Endoscopic non-remission (n = 29)	Endoscopic remission (n = 8)	*P*-value
IUS parameters at early post-treatment			
BWT (mm), mean ± SD	5.5 ± 1.2	5.5 ± 2.5	0.955
Limberg, No. (%)			0.067
Limberg = 0	1 (3)	1 (13)	
Limberg = 1	9 (31)	1 (13)	
Limberg = 2	13 (45)	1 (13)	
Limberg = 3	6 (21)	5 (63)	
Limberg = 4	0	0	
MUC, mean ± SD	8.9 ± 2.4	9.2 ± 4.2	0.869
Wall layer stratification, No. (%)			0.843
Loss	17 (59)	5 (63)	
Blurred	12 (41)	3 (38)	
Clear	0	0	
△BWT, mean ± SD	1.9 ± 1.7	2.1 ± 2.4	0.720
△MUC, mean ± SD	3.0 ± 2.8	3.5 ± 3.9	0.672

[a]Among the 8 patients in the endoscopic remission group, 1 patient received mesalazine as the initial induction treatment and therefore was not included in the corticosteroids, VDZ, IFX, or JAK1 inhibitor categories.
VDZ, Vedolizumab; IFX, Infliximab; JAK, Janus kinase; MES, Mayo endoscopic subscore; CRP, C-reactive protein; ESR, Erythrocyte sedimentation rate; IUS, Intestinal ultrasound; BWT, Bowel wall thickness; MUC, Milan ultrasound criteria.

https://doi.org/10.5217/ir.2025.00286